Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

Bibliographic Details
Title:	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Authors:	Tabernero, Josep, Yoshino, Takayuki, Cohn, Allen Lee, Obermannova, Radka, Bodoky, Gyorgy, Garcia-Carbonero, Rocio, Ciuleanu, Tudor-Eliade, Portnoy, David C, Van Cutsem, Eric, Grothey, Axel, Prausová, Jana, Garcia-Alfonso, Pilar, Yamazaki, Kentaro, Clingan, Philip R, Lonardi, Sara, Kim, Tae Won, Simms, Lorinda, Chang, Shao-Chun, Nasroulah, Federico
Source:	In The Lancet Oncology May 2015 16(5):499-508
Database:	ScienceDirect